Literature DB >> 9721246

A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.

T Cihlar1, M D Fuller, A S Mulato, J M Cherrington.   

Abstract

In cell culture, cidofovir (CDV) was used to select a human cytomegalovirus (HCMV) strain with decreased drug susceptibility. The genotypic characterization of this virus revealed a single base substitution resulting in a K513N amino acid alteration in the viral DNA polymerase (UL54). Performed in parallel, the selection of HCMV for replication in the presence of ganciclovir (GCV) selected an M460V substitution in the phosphotransferase (UL97), as well as a K513N/V812L double substitution in DNA polymerase. Neither of the two DNA polymerase mutations has been previously identified in HCMV drug-resistant strains. To precisely elucidate their role in drug resistance, corresponding recombinant mutant viruses were generated by recombination of nine overlapping viral DNA fragments. The K513N recombinant virus showed 13- and 6.5-fold decreased susceptibility to CDV and GCV in vitro, respectively, compared with the wild-type recombinant virus. Mutation V812L was associated with a moderate (2-3-fold) decrease in susceptibility to CDV, GCV, foscarnet, and adefovir. A multiplicative interaction of the K513N and V812L mutations with regard to the profile and level of drug resistance was demonstrated in recombinant virus expressing both mutations. In vitro replication kinetic experiments revealed that the K513N mutation significantly decreased HCMV replication capacity. Consistent with this finding, the K513N mutant DNA polymerase exhibited reduced specific activity in comparison with the wild-type enzyme and was severely impaired in its 3'-5' exonuclease function. Unexpectedly, the K513N mutant enzyme showed no decrease in susceptibility to CDV-diphosphate or GCV-triphosphate. However, the K513N mutation decreased the susceptibility to CDV and GCV of the oriLyt plasmid replication in the transient transfection/infection assay, suggesting that the DNA replication of the K513N mutant virus is less sensitive to the corresponding inhibitors. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721246     DOI: 10.1006/viro.1998.9299

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.

Authors:  Anne-Marie Fillet; Laetitia Auray; Sophie Alain; Karine Gourlain; Berthe Marie Imbert; Fatiha Najioullah; Gael Champier; Stéphanie Gouarin; Jocelyne Carquin; Nadhira Houhou; Isabelle Garrigue; Alexandra Ducancelle; Danielle Thouvenot; Marie-Christine Mazeron
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 3.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.

Authors:  Meike Chevillotte; Ina Ersing; Thomas Mertens; Jens von Einem
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

6.  Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.

Authors:  Sunwen Chou; Gail I Marousek; Laura C Van Wechel; Shaobing Li; Adriana Weinberg
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

7.  Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

8.  Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.

Authors:  Scott H James; Nathan B Price; Caroll B Hartline; E Randall Lanier; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

9.  New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 10.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.